D-0100-2017 Class II Terminated

Recalled by Allergan Sales, LLC — Waco, TX

FDA drug recall D-0100-2017 was initiated by Allergan Sales, LLC on Jun 30, 2016 and is designated Class II. Reason for recall: Failed Content Uniformity Specifications The recall status is terminated (terminated Dec 6, 2017). Affected quantity: 17,112 tubes.

Recall details

Product Type
Drugs
Report Date
Oct 19, 2016
Initiation Date
Jun 30, 2016
Termination Date
Dec 6, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
17,112 tubes

Product description

TAZORAC (tazarotene) Gel 0.05%, Rx only, packaged in 15 x 3.5 g professional sample containers, Manufactured by: Allergan Inc., Irvine, CA 92512. UPC: 300238335159.

Reason for recall

Failed Content Uniformity Specifications

Distribution pattern

Nationwide

Code information

Lot # 85037; Exp 05/17 Lot # 82583; Exp 10/16

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0100-2017
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0100-2017. Report a data issue: hello@regdatalab.com.